The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 2

From BugSigDB


Reviewed Marked as Reviewed by Folakunmi on 2024-4-10

Curated date: 2024/03/29

Curator: Scholastica

Revision editor(s): Scholastica, Folakunmi, Victoria

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Non-responders (colorectal cancer - CRC)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Responders (colorectal cancer - CRC)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with colorectal cancer (CRC) who achieved an objective response (Partial Responders/Stable Disease) lasting at least 3 months upon treatment start with anti–PD-1/PD-L1 immunotherapy.
Group 0 sample size Number of subjects in the control (unexposed) group
7
Group 1 sample size Number of subjects in the case (exposed) group
12
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
None

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
raw counts
Statistical test
Zero-Inflated Negative Binomial Regression
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No

Alpha Diversity

Inverse Simpson Modification of Simpsons index D as 1/D to obtain high values in datasets of high diversity and vice versa
unchanged

Signature 1

Reviewed Marked as Reviewed by Folakunmi on 2024-4-9

Curated date: 2024/03/29

Curator: Scholastica

Revision editor(s): Scholastica

Source: Fig. 3B, Supp. Table S7

Description: Differential abundance between responders and non-responders to Anti–PD-1/PD-L1 immunotherapy in patients with Colorectal Cancer (CRC)

Abundance in Group 1: increased abundance in Responders (colorectal cancer - CRC)

NCBI Quality ControlLinks
Bacteroides
Dialister
Flavonifractor
Lachnoclostridium
Lachnospira
Parabacteroides
Ruminococcaceae bacterium UCG-005
Lachnospiraceae_AC2044_groupLachnospiraceae_AC2044_group
Ruminococcus_2Ruminococcus_2
uncultured Lachnospiraceae bacterium

Revision editor(s): Scholastica

Signature 2

Reviewed Marked as Reviewed by Folakunmi on 2024-4-9

Curated date: 2024/03/29

Curator: Scholastica

Revision editor(s): Scholastica

Source: Fig. 3B, Supp. Table S7

Description: Differential abundance between responders and non-responders to Anti–PD-1/PD-L1 immunotherapy in patients with Colorectal Cancer (CRC)

Abundance in Group 1: decreased abundance in Responders (colorectal cancer - CRC)

NCBI Quality ControlLinks
Bacteroides
Bifidobacterium
Lachnoclostridium
Odoribacter
Oscillibacter
Parabacteroides
Subdoligranulum
Coprococcus_2Coprococcus_2

Revision editor(s): Scholastica